Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye

Journal of Controlled Release

Volumn 145, Issue 3, 2010, Pages 297-305

  Hagigit, Tal ^a   Abdulrazik, Muhammad ^a   Orucov, Faik ^b   Valamanesh, Faty ^e   Lambert, Martin ^c   Lambert, Gregory ^d   Behar Cohen, Francine ^c   Benita, Simon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c INSERM   (France)

^d Novagali Pharma   (France)

^e FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

AMD; Cationic; DOTAP; Nanoemulsion; Oligonucleotide; VEGF

Indexed keywords

AMD; ANTISENSE OLIGONUCLEOTIDES; CELL NUCLEUS; EX-VIVO; IN-VITRO; IN-VIVO; INNER NUCLEAR LAYERS; INTRAVITREAL INJECTION; NANO-DROPLETS; NANO-EMULSIONS; NANOEMULSION; OCULAR TISSUE; POST INJECTION; RETINAL CELLS; THERAPEUTIC LEVELS; VEGFR-2; YIELD POTENTIAL;

DRUG THERAPY; NUCLEIC ACIDS; OLIGONUCLEOTIDES; OPHTHALMOLOGY;

EXPERIMENTS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE 17; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; CATION; EMULSION; NUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; RETINA CELL; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; EMULSION; EYE; GENETICS; LEWIS RAT; METABOLISM; RABBIT; RAT; TOPICAL DRUG ADMINISTRATION; TUMOR CELL LINE;

ADMINISTRATION, TOPICAL; ANIMALS; CATIONS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; EMULSIONS; EYE; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; RABBITS; RATS; RATS, INBRED LEW; THIONUCLEOTIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77954314021     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.04.013     Document Type: Article

References (25)

1. Shachat A.P. New treatments for age-related macular degeneration. Ophthalmology 2005, 112:531-532.
2. Shams N., Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol. Clin. North Am. 2006, 19:335-344.
3. Bressler S.B. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009, 116:S1-S7.
4. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 14:1419-1431. MARINA Study Group.
5. Kroll P., Meyer C.H. Which treatment is best for which AMD patient?. Br. J. Ophthalmol. 2006, 90:128-130.
6. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002, 22:143-152. Eyetech Study Group.
7. Jager R.D., Aiello L.P., Patel S.C., Cunningham E.T. Risks of intravitreous injection: a comprehensive review. Retina 2004, 24:676-698.
8. Ta C.N. Minimizing the risk of endophthalmitis following intravitreous injections. Retina 2004, 24:699-705.
9. Aiello L.P., Brucker A.J., Chang S., Cunningham E.T., D'Amico D.J., Flynn H.W., Grillone L.R., Hutcherson S., Liebmann J.M., O'Brien T.P., Scott I.U., Spaide R.F., Ta C., Trese M.T. Evolving guidelines for intravitreous injections. Retina 2004, 24:S3-S19.
10. Garrett K.L., Shen W.Y., Rakoczy P.E. In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye. J. Gene Med. 2001, 3:373-383.
11. Gatto B., Cavalli M. From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy. Anticancer Agents Med. Chem. 2006, 6:287-301.
12. Gomes dos Santos A.L., Bochot A., Tsapis N., Artzner F., Bejjani R.A., Thillaye-Goldenberg B., de Kozak Y., Fattal E., Behar-Cohen F. Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy. Pharm. Res. 2006, 23:770-781.
13. Fattal E., Barratt G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br. J. Pharmacol. 2009, 157:179-194.
14. Hussain M., Shchepinov M., Sohail M., Benter I.F., Hollins A.J., Southern E.M., Akhtar S. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. J. Control. Release 2004, 99:139-155.
15. Akhtar S., Hughes M.D., Khan A., Bibby M., Hussain M., Nawaz Q., Double J., Sayyed P. The delivery of antisense therapeutics. Adv. Drug Deliv. Rev. 2000, 44:3-21.
16. Teixeira H., Dubernet C., Puisieux F., Benita S., Couvreur P. Submicron cationic emulsions as a new delivery system for oligonucleotides. Pharm. Res. 1999, 16:30-36.
17. Yang S.C., Benita S. Enhanced absorption and drug targeting by positively charged submicron emulsions. Drug Dev. Res. 2000, 50:476-486.
18. Tamilvanan S., Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur. J. Pharm. Biopharm. 2004, 58:357-368.
19. Teixeira H., Dubernet C., Rosilio V., Laigle A., Deverre R.R., Scherman D., Benita S., Couvreur P. Factors influencing the oligonucleotides release from O/W submicron cationic emulsions. J. Control. Release 2001, 70:243-255.
20. Hagigit T., Nassar T., Behar-Cohen F., Lambert G., Benita S. The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions. Eur. J. Pharm. Biopharm. 2008, 70:248-259.
21. Rabinovich-Guilatt L., Couvreur P., Lambert G., Goldstein D., Benita S., Dubernet C. Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem. Phys. Lipids 2004, 131:1-13.
22. Harush-Frenkel O., Debotton N., Benita S., Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 2007, 353:26-32.
23. Harush-Frenkel O., Rozentur E., Benita S., Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 2008, 9:435-443.
24. Csaky K. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology 2003, 110:879-881.
25. Bell C., Lynam E., Landfair D.J., Janjic N., Wiles M.E. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell. Dev. Biol. Anim. 1999, 35:533-542.